To #cycle within or go to another drug class I #axSpA? #RCT of #TNFi-IR 👇 2nd #TNFi v #IL17i #IJDM it doesn’t matter what choice as #IL17i WAS NOT superior to TNFi cycling from 1st -2nd 👍 stay in #TNFi class = change to #IL17i #ACR25 @RheumNow abst#LB09 #ACRBest @ACRheum https://t.co/VCdL5CUYUa

The CLASSIC study validated the performance of the 2009 ASAS classification criteria Model A was chosen for the revised criteria since it achieved prespecified performance targets of SN ≥75% and SP ≥90% 🔸Pso was included 🔸⬆️CRP replaced dactylitis #ACR25 @RheumNow Abs0854 https://t.co/tK52rQyaRa

🎥 LIVE from #ACR25 Join us daily at 5 PM CST for RheumNow’s ACR Recap Live - Your must-watch debrief of the day’s biggest breakthroughs, hot abstracts, and real-time clinical takeaways. Streaming on YouTube Live, Facebook Live, X-Live & LinkedIn Live. Save the time. Be part of https://t.co/xn4yUta9Da

In a global retrospective study of 90,536 PsA patients, those on GLP-1 receptor agonists (n=4,104) had significantly lower risk of major cardiovascular events and reduced mortality vs non-users. Most common GLP-1 RA: semaglutide. Supports future research on cardiometabolic https://t.co/ccOL10gD5b

Time for the 2nd plenary session! 🎤 #0849 GLP-1 receptor agonists in #PsA linked with lower mortality & fewer major cardiac events in >90K patients. Promising data for inflammation, weight & heart health in PsA care. @RheumNow #ACR25 https://t.co/8zyrSrumOP

This morning in the plenary, same theme, but in PsA: Similar metabolic/CV concerns Similarly benefit from GLP-1 RA looking at TriNetX data again, reduced MACE Now prospective trials in rheum disease, for both metabolic benefits & disease activity? #ACR25 ABST0849 @RheumNow https://t.co/DHZN1hwbIG

GLP-1 RA meds: we are just starting to see their impact in rheumatoid arthritis. We know metabolic, CV risk in RA, but what to do? RA pts in TriNetX, obese non-diabetic GLP-1 RA reduced 1y CV events & also all-cause mortality Soon will be near-standard #ACR25 ABST0445 @RheumNow https://t.co/4ptAHdmf9q

Key slide and takeaways on the ACR 2025 extrarenal SLE guideline. Presented by Lisa Sammaritano @RheumNow #ACR25 #ACRBest https://t.co/Xa97O6RdBY

Crisci et al. from CorEvitas. Alcohol, esp moderate use, associated lower CDAI. Most likely explanation appears to be residual confounders based on impact of adjustments however... @RheumNow #ACR25 Abstr#1340 https://t.co/cd0JLW8nGD

#ACR25 Abstr#0773 Anti-MDA5 ab is assoc. with progressive DM-ILD. But MDA5 expression is also upregulated in IPF. Any new biomarker which can link these ILD? Measuring reactivity to MDA5 (aa 201-300) epitope peptide may help identify poor ILD prognostics (with/out DM) @RheumNow https://t.co/rziwihKfIr

What is the #frequency of #CTD #ILD in #USA? Data from #Marketscan >9K & #Optum ~20k CTD-ILD Pts 56-65 yrs, 3/4 F ?under ascertained #RA-ILD - low % but #SSc-ILD approx 16% clinically relevant Same as Ont, Canada #SSc-ILD % Not rare #ACR25 @RheumNow @ACRheum Abst#0154 https://t.co/imfSyOtYpC